KRAS and non-small cell lung carcinoma: While association with prognosis is controversial,9 effective KRAS-targeted therapies were not available until recently, when evidence has emerged about therapeutic activity of the specific inhibitor AMG-510 in G12C KRAS-mutated NSCLC.10